Adefule-Ositelu A O, Onakoya A O, Olasimbo O O, Adefule A K
Guiness Eye Centre, Lagos University Teaching Hospital, Idi-Araba, Nigeria.
Niger Postgrad Med J. 2006 Mar;13(1):35-40.
To ascertain the efficacy of Lodoxamide 0.1 in the reduction of Clinicopathological signs of the conjunctiva in Vernal Keratoconjunctivitis.
Prospective, non-comparative, Convenient Interventional Case Series.
One Hundred consecutive patients; 57 males and 43 females within age range 2-55 years diagnosed with active and untreated Vernal conjunctivitis were enrolled. Approval was obtained from Ethical committee of Lagos University Teaching Hospital, Idi- Araba, Lagos.
Patients were given a bottle of Lodoxamide 0.1 each to instill four times daily into both eyes. Pre-treatment Clinical photographs and conjunctival biopsies were taken in 15 volunteered patients. Ocular signs and symptoms were evaluated on day 1 (baseline), days 2-3 (Interim) and then weekly for 6 weeks (final). Post treatment Clinical photographs and conjunctival biopsies were done at the 6th week. The conjunctival tissues were fixed for 24 hours in 10 Neutral buffered formalin prior to paraffin wax embedding and routinely stained with Haematoxylin and Eosin (H & E) stains.
Primary outcome was based on the reduction of inflammatory cells especially the eosinophils on histological micrographs. Secondary efficacy was based on the rate and extent of reduction of the severity scores of the clinical signs and symptoms.
Lodoxamide 0.1 ophthalmic solution significantly reduced the density of the inflammatory cells especially eosinophils in the post treatment conjunctival biopsy cytology specimen. The mean physician severity scores for signs and symptoms consistently reduced from 72 hours of commencement of Lodoxamide with remarkable improvement in a week and complete resolution of all parameters at the end of 5th week.
Lodoxamide 0.1 ophthalmic solution is highly effective in alleviating the clinical signs and symptoms of Vernal Keratoconjunctivitis and its antiallergic activity is exerted by inhibiting migration of inflammatory cells mainly eosinophlis.
确定0.1%洛度沙胺在减轻春季角结膜炎结膜的临床病理体征方面的疗效。
前瞻性、非对照、便利干预病例系列。
连续入选100例患者；年龄在2至55岁之间的57例男性和43例女性，均被诊断为活动性且未经治疗的春季结膜炎。获得了拉各斯伊迪-阿拉巴市拉各斯大学教学医院伦理委员会的批准。
给每位患者一瓶0.1%洛度沙胺，每天双眼各滴注4次。对15名自愿参与的患者进行治疗前临床照片拍摄和结膜活检。在第1天（基线）、第2至3天（中期）进行眼部体征和症状评估，然后每周评估1次，共6周（末期）。在第6周进行治疗后临床照片拍摄和结膜活检。结膜组织在10%中性缓冲福尔马林中固定24小时，然后进行石蜡包埋，并常规用苏木精和伊红（H&E）染色。
主要结局基于组织学显微照片上炎症细胞尤其是嗜酸性粒细胞数量的减少。次要疗效基于临床体征和症状严重程度评分的降低率和降低程度。
0.1%洛度沙胺滴眼液显著降低了治疗后结膜活检细胞学标本中炎症细胞尤其是嗜酸性粒细胞的密度。从开始使用洛度沙胺72小时起，医生对体征和症状的平均严重程度评分持续降低，1周内有显著改善，在第5周结束时所有参数完全恢复正常。
0.1%洛度沙胺滴眼液在减轻春季角结膜炎的临床体征和症状方面非常有效，其抗过敏活性是通过抑制主要是嗜酸性粒细胞的炎症细胞迁移来发挥作用的。
